1
|
Saro G, Johne S, Latino DARS, Moine F, van der Toorn M, Mathis C, Veljkovic E. Monoamine Oxidase Inhibitors Present in Tobacco Modulate Dopamine Balance Via the Dopamine Transporter. ACS Chem Neurosci 2025. [PMID: 40033845 DOI: 10.1021/acschemneuro.4c00789] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 03/05/2025] Open
Abstract
It has been reported that nicotine affects brain dopamine homeostasis. By binding to nicotinic acetylcholine receptors, including those expressed by dopaminergic neurons of the ventral tegmental area, nicotine stimulates dopamine release and signaling. Dopamine is taken up from the synaptic cleft by the dopamine transporter (DAT) into presynaptic neurons, where it is degraded by monoamine oxidase (MAO). Besides nicotine, other tobacco compounds play a role in dopamine modulation. To better understand the biological effects of nicotine and other tobacco compounds on dopamine regulation, we selected a group of tobacco compounds based on their potential affinity to bind human MAO-A and MAO-B enzymes using an in silico approach. Subsequently, we tested the putative compounds in an enzymatic assay to verify their ability to inhibit human MAO-A or MAO-B. The positive hits were harman, norharman, harmaline, and 1-ethyl-β-carboline. While harman and norharman have been extensively studied, both harmaline and 1-ethyl-β-carboline have not been described in the context of tobacco and MAO inhibition before. We investigated DAT activity in an overexpressing cell line and dopamine release and uptake in rat striatal synaptosomes. We clearly demonstrate that tested MAO-A inhibitors (MAO-AIs) significantly attenuated human DAT activity and consequent dopamine uptake, establishing a functional connection between MAOIs and dopamine uptake via DAT. Interestingly, the tested MAO-AIs elicited pronounced dopamine release in crude synaptosomal preparations. In summary, this in vitro study demonstrates that tested MAO-AIs found in cigarette smoke not only reduce MAO activity but also strongly impact dopamine homeostatic mechanisms via DAT. Further in vivo investigations would advance our understanding of the underlying mechanisms of dopamine regulation and homeostasis.
Collapse
Affiliation(s)
- Gabriella Saro
- PMI R&D, Philip Morris Products S.A., Quai Jeanrenaud 5, 2000 Neuchâtel, Switzerland
| | - Stephanie Johne
- PMI R&D, Philip Morris Products S.A., Quai Jeanrenaud 5, 2000 Neuchâtel, Switzerland
| | | | - Fabian Moine
- PMI R&D, Philip Morris Products S.A., Quai Jeanrenaud 5, 2000 Neuchâtel, Switzerland
| | - Marco van der Toorn
- PMI R&D, Philip Morris Products S.A., Quai Jeanrenaud 5, 2000 Neuchâtel, Switzerland
| | - Carole Mathis
- PMI R&D, Philip Morris Products S.A., Quai Jeanrenaud 5, 2000 Neuchâtel, Switzerland
| | - Emilija Veljkovic
- PMI R&D, Philip Morris Products S.A., Quai Jeanrenaud 5, 2000 Neuchâtel, Switzerland
| |
Collapse
|
2
|
Truman P, Atigari DV, Kidwell M, Colussi-Mas J, Ellenbroek B. The effect of mixed tobacco monoamine oxidase inhibitors in animal models relevant to tobacco dependence. Psychopharmacology (Berl) 2025; 242:617-628. [PMID: 39556208 DOI: 10.1007/s00213-024-06712-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/22/2024] [Accepted: 10/30/2024] [Indexed: 11/19/2024]
Abstract
RATIONALE Tobacco monoamine oxidase (MAO) inhibitors have long been suspected of influencing tobacco dependence, but direct evidence of their effects has been difficult to obtain. Recently we have identified two new groups of monoamine oxidase inhibitors, hydroquinones and polyunsaturated fatty acids (linoleic and linolenic acid), abundant in tobacco smoke. OBJECTIVES To test, in relevant animal models, whether the combined effect of these inhibitors is sufficient to affect addictive responses to nicotine. METHODS Here we report the first tests of the effects of mixed tobacco MAO inhibitors in three animal behavioural tests relevant to nicotine addiction, conditioned place preference, locomotor sensitisation and nicotine self-administration. Inhibitors used were the aforementioned linoleic and linolenic acid, and catechol, 4-ethylcatechol, 4-methyl catechol and hydroquinone, together with the already known inhibitors harman and norharman. They were administered together in the ratios found in tobacco smoke. RESULTS In conditioned place preference and in self-administration tests the addition of these tobacco MAO inhibitors significantly increased responding to nicotine and motivation to self-administer nicotine, supporting the hypothesis that inhibition of MAO enzymes in the brain enhances addictive responses such as that for nicotine. The combined MAO inhibitors without nicotine did not cause increased locomotor activity and did not induce a place conditioned response. CONCLUSIONS Our results show that the combined effect of three groups of major MAO inhibitors present in tobacco smoke can enhance the addictive responses to nicotine in rats. There is no evidence from this study that these MAO inhibitors are addictive in themselves.
Collapse
Affiliation(s)
- Penelope Truman
- School of Health Sciences, Massey University, Wellington, New Zealand.
| | | | - Meyrick Kidwell
- School of Psychology, Victoria University of Wellington, Wellington, New Zealand
| | - Joyce Colussi-Mas
- School of Biological Sciences, Victoria University of Wellington, Wellington, New Zealand
| | - Bart Ellenbroek
- School of Psychology, Victoria University of Wellington, Wellington, New Zealand
| |
Collapse
|
3
|
Zhong M, Hou W, Liu Z, Wang F, Yang J, Xu Y, Long X, Chen Y, Kang Y, Wang Y, Wang Y, Zhang M, Yang J. Temporal dynamic changes of intrinsic brain regional activity in depression with smoking. J Affect Disord 2025; 377:S0165-0327(25)00268-X. [PMID: 39988134 DOI: 10.1016/j.jad.2025.02.061] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/01/2024] [Revised: 02/13/2025] [Accepted: 02/17/2025] [Indexed: 02/25/2025]
Abstract
BACKGROUND Depression is often accompanied by high levels of smoking behavior, and smoking can act as a risk factor for depression. However, there is limited neuroimaging evidence regarding the association between depression and smoking, especially the impact of this association on the brain stability remains unclear. Therefore, this study aimed to assess the interaction effect between smoking and depression from a neurodynamic perspective. METHOD We assessed the resting-state functional magnetic resonance imaging from 193 participants (55 depressed smokers; 51 depressed non-smokers; 25 healthy smokers; 62 healthy non-smokers) and calculated 3 regional activity dynamic indicators, including dynamic regional homogeneity (dReHo), dynamic amplitude of low-frequency fluctuations (dALFF), and dynamic fractional ALFF (dfALFF). Principal component analysis was conducted on these 3 dynamic indicators, and the first component was extracted for the subsequent 2 × 2 factor designs statistical analysis. RESULT We observed the interaction between smoking and depression increases the instability of regional activity in the precentral gyrus and precuneus. Compared with HCs, patients with depression showed increased instability of regional activity across widespread regions such as the precentral gyrus, thalamus, and medial frontal gyrus. No main effects of smoking were observed. In depressed smokers, the instability of regional activity in left precuneus is positively correlated with anxiety symptoms. CONCLUSIONS Our findings indicate that smoking potentially exacerbates brain abnormal instability in depression, implying a clinical need to require patients with depression to abstain from smoking.
Collapse
Affiliation(s)
- Maoxing Zhong
- Department of Psychiatry, National Clinical Research Center for Mental Disorders, and National Center for Mental Disorders, The Second Xiangya Hospital of Central South University, Changsha 410011, Hunan, China
| | - Wenfei Hou
- Department of Psychiatry, National Clinical Research Center for Mental Disorders, and National Center for Mental Disorders, The Second Xiangya Hospital of Central South University, Changsha 410011, Hunan, China
| | - Zhening Liu
- Department of Psychiatry, National Clinical Research Center for Mental Disorders, and National Center for Mental Disorders, The Second Xiangya Hospital of Central South University, Changsha 410011, Hunan, China
| | - Feiwen Wang
- Department of Psychiatry, National Clinical Research Center for Mental Disorders, and National Center for Mental Disorders, The Second Xiangya Hospital of Central South University, Changsha 410011, Hunan, China
| | - Jun Yang
- Department of Psychiatry, National Clinical Research Center for Mental Disorders, and National Center for Mental Disorders, The Second Xiangya Hospital of Central South University, Changsha 410011, Hunan, China
| | - YiFun Xu
- Department of Psychiatry, National Clinical Research Center for Mental Disorders, and National Center for Mental Disorders, The Second Xiangya Hospital of Central South University, Changsha 410011, Hunan, China
| | - Xinrui Long
- Department of Psychiatry, National Clinical Research Center for Mental Disorders, and National Center for Mental Disorders, The Second Xiangya Hospital of Central South University, Changsha 410011, Hunan, China
| | - Yaxuan Chen
- Department of Psychiatry, National Clinical Research Center for Mental Disorders, and National Center for Mental Disorders, The Second Xiangya Hospital of Central South University, Changsha 410011, Hunan, China
| | - Yiping Kang
- Department of Psychiatry, National Clinical Research Center for Mental Disorders, and National Center for Mental Disorders, The Second Xiangya Hospital of Central South University, Changsha 410011, Hunan, China
| | - Yuxi Wang
- Department of Psychiatry, National Clinical Research Center for Mental Disorders, and National Center for Mental Disorders, The Second Xiangya Hospital of Central South University, Changsha 410011, Hunan, China
| | - Yiju Wang
- Department of Psychiatry, National Clinical Research Center for Mental Disorders, and National Center for Mental Disorders, The Second Xiangya Hospital of Central South University, Changsha 410011, Hunan, China
| | - Miao Zhang
- Department of Psychiatry, National Clinical Research Center for Mental Disorders, and National Center for Mental Disorders, The Second Xiangya Hospital of Central South University, Changsha 410011, Hunan, China
| | - Jie Yang
- Department of Psychiatry, National Clinical Research Center for Mental Disorders, and National Center for Mental Disorders, The Second Xiangya Hospital of Central South University, Changsha 410011, Hunan, China.
| |
Collapse
|
4
|
van der Heijden KV, Otto ME, Schoones JW, van Esdonk MJ, Borghans LGJM, van Hasselt JGC, van Gerven JMA, Jacobs G. Clinical Pharmacokinetics of N,N-Dimethyltryptamine (DMT): A Systematic Review and Post-hoc Analysis. Clin Pharmacokinet 2025; 64:215-227. [PMID: 39838235 PMCID: PMC11782443 DOI: 10.1007/s40262-024-01450-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 10/24/2024] [Indexed: 01/23/2025]
Abstract
BACKGROUND AND OBJECTIVE N,N-Dimethyltryptamine (DMT) is currently being studied for its therapeutic potential in various psychiatric disorders. An understanding of its pharmacokinetics (PK) is essential to determine appropriate dose ranges in future clinical studies. We conducted a systematic literature review on the PK of DMT. METHODS Clinical studies that administered known amounts of DMT and reported PK data and/or parameters in humans were included. Additionally, raw PK data were requested from authors and/or extracted from publications. RESULTS In total, 219 references were retrieved, of which 13 publications were included, covering eight distinct datasets. All studies administered DMT intravenously in various infusion schemes, except for one intramuscular administration. High variability in dose-normalized exposure parameters and differences in exposure for bolus versus infusion administration were observed. DMT is extensively redistributed to other tissues, based on its biphasic elimination profile and high volume of distribution in the terminal elimination phase (range 123-1084 L). It is eliminated rapidly, with a half-life of 4.8-19.0 min and clearance of 8.1-46.8 L/min. This is a result of the rapid metabolization of DMT to indole-3-acetic acid (IAA), which is also reflected in the fact that the time of maximum concentration of IAA is similar to that of DMT. CONCLUSION This review demonstrates that the PK of DMT in humans have been characterized to a limited extent, and publications lack details with regards to demographics, absolute doses, and PK parameters. Additional studies are necessary to investigate high intersubject variability and differences in exposure following bolus or prolonged infusion. Addressing these issues is essential for the development of DMT as a pharmacotherapeutic in neuropsychiatry.
Collapse
Affiliation(s)
- K V van der Heijden
- Centre for Human Drug Research (CHDR), Leiden, The Netherlands.
- Leiden University Medical Centre (LUMC), Leiden University, Leiden, The Netherlands.
| | - M E Otto
- Centre for Human Drug Research (CHDR), Leiden, The Netherlands
- Leiden Academic Centre for Drug Research (LACDR), Leiden University, Leiden, The Netherlands
| | - J W Schoones
- Directorate of Research Policy, Leiden University Medical Center (LUMC), Leiden, The Netherlands
| | | | | | - J G C van Hasselt
- Leiden Academic Centre for Drug Research (LACDR), Leiden University, Leiden, The Netherlands
| | - J M A van Gerven
- Centre for Human Drug Research (CHDR), Leiden, The Netherlands
- Leiden University Medical Centre (LUMC), Leiden University, Leiden, The Netherlands
| | - G Jacobs
- Centre for Human Drug Research (CHDR), Leiden, The Netherlands
- Department of Psychiatry, Leiden University Medical Center (LUMC), Leiden University, Leiden, The Netherlands
| |
Collapse
|
5
|
Hong SW, Page R, Truman P. Smoking, coffee intake, and Parkinson's disease: Potential protective mechanisms and components. Neurotoxicology 2025; 106:48-63. [PMID: 39701424 DOI: 10.1016/j.neuro.2024.12.003] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/20/2024] [Revised: 12/05/2024] [Accepted: 12/14/2024] [Indexed: 12/21/2024]
Abstract
Parkinson's disease (PD) is a common progressive neurodegenerative disease characterized by the loss of dopaminergic neurons in the substantia nigra pars compacta (SNpc). Environmental and lifestyle factors, such as smoking and coffee drinking, have been associated with a decreased risk for PD. However, the biological mechanisms underlying protective effects on PD are still not fully understood. It has been suggested that non-nicotine components in cigarette smoke and non-caffeine components in coffee may contribute to this protective effect. The aim of this review was to explore candidate molecules and mechanisms behind the effects of smoking and coffee drinking on PD by integrating findings from previous studies. By cross-referencing an index of tobacco constituents and a list of coffee constituents with existing literature on natural compounds and their structural analogs that show inhibitory activities against monoamine oxidase B, catechol O-methyltransferase, and α-synuclein fibrillation, we have identified tobacco and coffee components that inhibit these targets. Furthermore, tobacco and coffee components potentially play roles in suppressing neuroinflammation, activating the Nrf2 pathway as natural activators, and altering the gut microbiome. This review suggests that the phenolic compounds from tobacco and coffee investigated may contribute to the low incidence of PD in smokers and coffee drinkers, showing moderate to strong potential as therapeutic interventions. The current review suggests that multifunctional molecules found in coffee and cigarette smoke may have potential neuroprotective effects, but none of the data indicates that multifunctionality is required for these effects. This review will deepen our understanding of how smoking and coffee drinking are linked to a reduced risk of PD and will also be important in elucidating the mechanisms underlying the protective effects of smoking and coffee drinking on PD.
Collapse
Affiliation(s)
- Sa Weon Hong
- School of Health Sciences, Massey University, Wellington 6021, New Zealand.
| | - Rachel Page
- School of Health Sciences, Massey University, Wellington 6021, New Zealand
| | - Penelope Truman
- School of Health Sciences, Massey University, Wellington 6021, New Zealand
| |
Collapse
|
6
|
Veronese N, Nova A, Fazia T, Riggi E, Yang L, Piccio L, Huang BH, Ahmadi M, Barbagallo M, Notarnicola M, Giannelli G, De Pergola G, Stamatakis E, Cereda E, Bernardinelli L, Fontana L. Contribution of Nutritional, Lifestyle, and Metabolic Risk Factors to Parkinson's Disease. Mov Disord 2024; 39:1203-1212. [PMID: 38532309 DOI: 10.1002/mds.29778] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/10/2023] [Revised: 02/21/2024] [Accepted: 02/23/2024] [Indexed: 03/28/2024] Open
Abstract
BACKGROUND Modifiable risk factors for Parkinson's disease (PD) are poorly known. OBJECTIVES The aim is to evaluate independent associations of different nutritional components, physical activity, and sedentary behavior and metabolic factors with the risk of PD. METHODS In this population-based prospective cohort study using the data of the United Kingdom Biobank (from 2006-2010), 502,017 men and women who were free from PD (International Classification of Diseases 10th edition; "G20") at baseline were included. We implemented a Cox proportion hazard's model to evaluate the associations of different levels of physical activity, sitting time, sleep habits, diet quality, alcohol and coffee consumption, smoking, and body mass index with PD risk, adjusting for several confounding variables. RESULTS During a median follow-up of 12.8 years, lifestyle factors including vigorous physical activity (hazard ration [HR] = 0.84; 95% confidence interval [CI], 0.75-0.94), low-to-moderate sitting time (HR = 0.89; 95% CI, 0.81-0.97), and high sleep quality (HR = 0.89; 95% CI, 0.80-0.99) were associated with a reduced risk of PD. Small amounts of coffee (HR = 0.88; 95% CI, 0.82-0.95), red meat (HR = 0.86; 95% CI, 0.76-0.97), and current smoking (HR = 0.65; 95% CI, 0.56-0.75) were also associated with a lower risk of PD, whereas alcohol intake (HR = 1.29; 95% CI, 1.06-1.56) with higher PD risk. Secondary analysis, including metabolic risk factors, confirmed these findings and highlighted the potential protective effect of plasma vitamin D and uric acid, but of low-density lipoprotein-cholesterol, triglycerides, and C-reactive protein as well. CONCLUSIONS Vigorous physical activity, reduced sitting time, good sleep quality together with small coffee intake and vitamin D supplementation are potentially neuroprotective lifestyle interventions for the prevention of PD. © 2024 International Parkinson and Movement Disorder Society.
Collapse
Affiliation(s)
- Nicola Veronese
- Geriatric Unit, Department of Internal Medicine and Geriatrics, University of Palermo, Palermo, Italy
| | - Andrea Nova
- Department of Brain and Behavioral Sciences, University of Pavia, Pavia, Italy
| | - Teresa Fazia
- Department of Brain and Behavioral Sciences, University of Pavia, Pavia, Italy
| | - Emilia Riggi
- Department of Brain and Behavioral Sciences, University of Pavia, Pavia, Italy
| | - Lin Yang
- Cancer Epidemiology and Prevention Research Alberta Health Services-Cancer Care Alberta, Calgary, Alberta, Canada
- Departments of Oncology and Community Health Sciences, University of Calgary, Calgary, Alberta, Canada
| | - Laura Piccio
- Charles Perkins Center, Faculty of Medicine and Health, University of Sydney, Sydney, New South Wales, Australia
- Brain and Mind Centre, Faculty of Medicine and Health, University of Sydney, Sydney, New South Wales, Australia
- Department of Neurology, Washington University, St. Louis, Missouri, USA
| | - Bo-Huei Huang
- Charles Perkins Center, Faculty of Medicine and Health, University of Sydney, Sydney, New South Wales, Australia
- School of Public Health, Faculty of Health, University of Technology Sydney, Sydney, New South Wales, Australia
| | - Matthew Ahmadi
- Charles Perkins Center, Faculty of Medicine and Health, University of Sydney, Sydney, New South Wales, Australia
| | - Mario Barbagallo
- Geriatric Unit, Department of Internal Medicine and Geriatrics, University of Palermo, Palermo, Italy
| | - Maria Notarnicola
- National Institute of Gastroenterology IRCCS "Saverio de Bellis", Castellana Grotte, Italy
| | - Gianluigi Giannelli
- National Institute of Gastroenterology IRCCS "Saverio de Bellis", Castellana Grotte, Italy
| | - Giovanni De Pergola
- National Institute of Gastroenterology IRCCS "Saverio de Bellis", Castellana Grotte, Italy
| | - Emmanuel Stamatakis
- Charles Perkins Center, Faculty of Medicine and Health, University of Sydney, Sydney, New South Wales, Australia
| | - Emanuele Cereda
- Clinical Nutrition and Dietetics Unit, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
- Fondazione Grigioni per il Morbo di Parkinson, Milan, Italy
| | - Luisa Bernardinelli
- Department of Brain and Behavioral Sciences, University of Pavia, Pavia, Italy
| | - Luigi Fontana
- Charles Perkins Center, Faculty of Medicine and Health, University of Sydney, Sydney, New South Wales, Australia
- Department of Endocrinology, Royal Prince Alfred Hospital, Sydney, New South Wales, Australia
| |
Collapse
|
7
|
Wang B, Shi Y, Zhang H, Hu Y, Chen H, Liu Y, Wang F, Chen L. Influence of microorganisms on flavor substances and functional components of sojae semen praeparatum during fermentation: A study integrating comparative metabolomics and high-throughput sequencing. Food Res Int 2024; 187:114405. [PMID: 38763659 DOI: 10.1016/j.foodres.2024.114405] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/15/2023] [Revised: 04/16/2024] [Accepted: 04/20/2024] [Indexed: 05/21/2024]
Abstract
Sojae semen praeparatum (SSP), a fermented product known for its distinctive flavor and medicinal properties, undergoes a complex fermentation process due to the action of various microorganisms. Despite its widespread use, the effect of these microorganisms on the flavor compounds and functional components of SSP remains poorly understood. This study aimed to shed light on this aspect by identifying 20 metabolites as potential key flavor substances in SSP. Moreover, glycine and lysine were identified as crucial flavor substances. Additionally, 24 metabolites were identified as key functional components. The dominant microorganisms involved in the fermentation process were examined, revealing six genera of fungi and 12 genera of bacteria. At the species level, 16 microorganisms were identified as dominant through metagenome sequencing. Spearman correlation analysis demonstrated a strong association between dominant microorganisms and both flavor substances and functional components. Furthermore, the study validated the significance of four core functional microorganisms in improving the flavor and quality of SSP. This comprehensive exploration of functional microorganisms of SSP on key flavor substances/functional components during SSP fermentation. The study findings serve as a valuable reference for enhancing the overall flavor and quality of SSP.
Collapse
Affiliation(s)
- Bin Wang
- State Key Laboratory of Southwestern Chinese Medicine Resources, Department of Pharmacy, Chengdu University of TCM, Chengdu, Sichuan, China
| | - Yifan Shi
- State Key Laboratory of Southwestern Chinese Medicine Resources, Department of Pharmacy, Chengdu University of TCM, Chengdu, Sichuan, China
| | - Hongyi Zhang
- State Key Laboratory of Southwestern Chinese Medicine Resources, Department of Pharmacy, Chengdu University of TCM, Chengdu, Sichuan, China
| | - Yuan Hu
- State Key Laboratory of Southwestern Chinese Medicine Resources, Department of Pharmacy, Chengdu University of TCM, Chengdu, Sichuan, China
| | - Hongping Chen
- State Key Laboratory of Southwestern Chinese Medicine Resources, Department of Pharmacy, Chengdu University of TCM, Chengdu, Sichuan, China
| | - Youping Liu
- State Key Laboratory of Southwestern Chinese Medicine Resources, Department of Pharmacy, Chengdu University of TCM, Chengdu, Sichuan, China
| | - Fu Wang
- State Key Laboratory of Southwestern Chinese Medicine Resources, Department of Pharmacy, Chengdu University of TCM, Chengdu, Sichuan, China.
| | - Lin Chen
- State Key Laboratory of Southwestern Chinese Medicine Resources, Department of Pharmacy, Chengdu University of TCM, Chengdu, Sichuan, China.
| |
Collapse
|
8
|
Parro-Torres C, Casas M, Martínez-Raga J, Pinet Ogué MC, Sáiz Martínez PA, Szerman N. Tobacco use disorder and other mental disorders: The neglected dual disorder. SPANISH JOURNAL OF PSYCHIATRY AND MENTAL HEALTH 2024:S2950-2853(24)00029-2. [PMID: 38740329 DOI: 10.1016/j.sjpmh.2024.04.002] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Received: 02/12/2024] [Revised: 04/23/2024] [Accepted: 04/24/2024] [Indexed: 05/16/2024]
Affiliation(s)
- Carlos Parro-Torres
- Institute of Psychiatry and Mental Health, Gregorio Marañón University General Hospital, Madrid, Spain.
| | - Miquel Casas
- Institut MIND, Hospital Sant Joan de Déu, Barcelona, Spain
| | - José Martínez-Raga
- Department of Psychiatry and Clinical Psychology, Hospital Universitario Doctor Peset, University of Valencia, Valencia, Spain
| | - Ma Cristina Pinet Ogué
- Addictive Behavior Unit, Psychiatry Department, Hospital de la Santa Creu i Sant Pau, Campus Salut, Barcelona, Spain
| | - Pilar Alejandra Sáiz Martínez
- Department of Psychiatry, Universidad de Oviedo, Oviedo, Spain; Centro de Investigación Biomédica en Red en Salud Mental (CIBERSAM)-Instituto de Salud Carlos III, Oviedo, Spain; Instituto de Investigación Sanitaria del Principado de Asturias (ISPA), Oviedo, Spain; Instituto Universitario de Neurociencias del Principado de Asturias (INEUROPA), Oviedo, Spain; Servicio de Salud del Principado de Asturias (SESPA), Oviedo, Spain
| | - Néstor Szerman
- Institute of Psychiatry and Mental Health, Gregorio Marañón University General Hospital, Madrid, Spain
| |
Collapse
|
9
|
Hung CC, Ko YC, Chung CM. Association between Single Nucleotide Polymorphisms in Monoamine Oxidase and the Severity of Addiction to Betel Quid. Curr Issues Mol Biol 2024; 46:1010-1019. [PMID: 38392182 PMCID: PMC10887354 DOI: 10.3390/cimb46020064] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/14/2023] [Revised: 01/19/2024] [Accepted: 01/22/2024] [Indexed: 02/24/2024] Open
Abstract
Betel quid (BQ) is the fourth most popular psychoactive substance in the world, and BQ use disorder (BUD) is prevalent in Asian countries. Although the mechanisms underlying BUD remain unclear, studies have reported influences from monoamine oxidase inhibitor. We enrolled 50 patients with BUD and assessed their BQ consumption habits, emotional conditions, and the clinical severity of addiction-assessed using the Diagnostic and Statistical Manual of Mental Disorders [Fifth Edition] (DSM-5) criteria, Substance Use Severity Rating Scale, and Yale-Brown Obsessive Compulsive Disorder Rating Scale for BQ. Patients were categorized into the severe group when showing six or more symptoms defined by DSM-5. A genome-wide association study was conducted for single nucleotide polymorphisms in BRCA1, COL9A1, NOTCH1, HSPA13, FAT1, and MAOA by using patients' blood samples. More severe BUD symptoms were associated with younger age of using BQ and poor oral hygiene and with severe craving for and more anxiety toward BQ use. The MAOA rs5953210 polymorphism was significantly associated with severe BUD (odds ratio, 6.43; 95% confidence interval, 5.12-7.74; p < 0.01) and might contribute to BQ-associated cancer risk. Further studies are required to investigate the addictive properties of BQ and the development of novel diagnostic tools and pharmacotherapeutic alternatives to BUD treatment.
Collapse
Affiliation(s)
- Chung-Chieh Hung
- School of Medicine, Chung Shan Medical University, Taichung 40201, Taiwan
- Department of Psychiatry, Chung Shan Medical University Hospital, Taichung 40201, Taiwan
| | - Ying-Chin Ko
- Department of Medical Research, China Medical University Hospital, China Medical University, Taichung 40447, Taiwan
- Graduate Institute of Toxicology, College of Medicine, National Taiwan University, Taipei 106216, Taiwan
| | - Chia-Min Chung
- Graduate Institute of Biomedical Sciences, China Medical University, Taichung 40402, Taiwan
- Department of Psychiatry and Center for Addiction and Mental Health, China Medical University Hospital, Taichung 404327, Taiwan
| |
Collapse
|
10
|
Varshney KK, Gupta JK, Srivastava R. Unveiling the Molecular Mechanism of Diosmetin and its Impact on Multifaceted Cellular Signaling Pathways. Protein Pept Lett 2024; 31:275-289. [PMID: 38629379 DOI: 10.2174/0109298665294109240323033601] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/03/2024] [Revised: 02/23/2024] [Accepted: 02/28/2024] [Indexed: 08/13/2024]
Abstract
BACKGROUND Diosmetin is an O-methylated flavone and the aglycone part of the flavonoid glycosides diosmin that occurs naturally in citrus fruits. Pharmacologically, diosmetin is reported to exhibit anticancer, antimicrobial, antioxidant, oestrogenic, and anti-inflammatory activities. OBJECTIVE This comprehensive review was aimed to critically explore diverse pharmacological activities exhibited by diosmetin. Along with that, this review can also identify potential research areas with an elucidation of the multifactorial underlying signaling mechanism of action of diosmetin in different diseases. METHODS A comprehensive collection of evidence and insights was obtained from scientific journals and books from physical libraries and electronic platforms like Google Scholar and PubMed. The time frame selected was from year 1992 to July 2023. RESULTS The review delves into diosmetin's impact on cellular signaling pathways and its potential in various diseases. Due to its ability to modulate signaling pathways and reduce oxidative stress, it can be suggested as a potential versatile therapeutic agent for mitigating oxidative stressassociated pathogenesis. CONCLUSION The amalgamation of the review underscores diosmetin's promising role as a multifaceted therapeutic agent, highlighting its potential for drug development and clinical applications.
Collapse
Affiliation(s)
| | | | - Rajnish Srivastava
- Moradabad Educational Trust Group of Institutions Faculty of Pharmacy, Moradabad, Uttar Pradesh, India
| |
Collapse
|
11
|
Truman P. Commentary: Harmane potentiates nicotine reinforcement through MAO-A inhibition at the dose related to cigarette smoking. Front Mol Neurosci 2023; 16:1119538. [PMID: 36825277 PMCID: PMC9941319 DOI: 10.3389/fnmol.2023.1119538] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/08/2022] [Accepted: 01/20/2023] [Indexed: 02/10/2023] Open
|